Influencing factors of NT-proBNP level inheart failure patients with different cardiacfunctions and correlation with prognosis
Gorde:
| Argitaratua izan da: | Experimental and Therapeutic Medicine vol. 15, no. 6 (2018), p. 5275 |
|---|---|
| Egile nagusia: | |
| Beste egile batzuk: | , , |
| Argitaratua: |
Spandidos Publications UK Ltd.
|
| Gaiak: | |
| Sarrera elektronikoa: | Citation/Abstract Full Text Full Text - PDF |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|
MARC
| LEADER | 00000nab a2200000uu 4500 | ||
|---|---|---|---|
| 001 | 2095422183 | ||
| 003 | UK-CbPIL | ||
| 022 | |a 1792-0981 | ||
| 022 | |a 1792-1015 | ||
| 024 | 7 | |a 10.3892/etm.2018.6114 |2 doi | |
| 035 | |a 2095422183 | ||
| 045 | 2 | |b d20180101 |b d20181231 | |
| 100 | 1 | |a Xu, Liang | |
| 245 | 1 | |a Influencing factors of NT-proBNP level inheart failure patients with different cardiacfunctions and correlation with prognosis | |
| 260 | |b Spandidos Publications UK Ltd. |c 2018 | ||
| 513 | |a Journal Article | ||
| 520 | 3 | |a Factors influencing N-terminal pro-brain natriuretic peptide (NT-proBNP) level in heart failure patients with different cardiac functions were identified to explore the correlations with prognosis. Eighty heart failure patients with different cardiac functions treated in Yixing People's Hospital from January 2016 to June 2017 were selected, and divided into two groups (group with cardiac function in class II and below and group with cardiac function in class III and above), according to the cardiac function classification established by New York Heart Association (NYHA). Blood biochemical test and outcome analysis were conducted to measure serum NT-proBNP and matrix metalloproteinase-9 (MMP-9) levels in patients with different cardiac functions, and correlations between levels of NT-proBNP and MMP-9 and left ventricular ejection fraction (LVEF) level were analyzed in patients with different cardiac functions at the same time. In addition, risk factors for heart failure in patients with different cardiac functions were analyzed. Compared with the group with cardiac function in class III and above, the group with cardiac function in class II and below had significantly lower serum NT-proBNP and MMP-9 levels (p<0.05). For echocardiogram indexes, left ventricular end-diastolic diameter (LVEDD) and left ventricular end-systolic diameter (LVESD) in the group with cardiac function in class II and below were obviously lower than those in the group with cardiac function in class III and above (p<0.05), while LVEF was higher in group with cardiac function in class II and below than that in group with cardiac function in class III and above (p<0.05). NT-proBNP and MMP-9 levels were negatively correlated with LVEF level [r=−0.8517 and −0.8517, respectively, p<0.001 (<0.05)]. Cardiac function in class III and above, increased NT-proBNP, increased MMP-9 and decreased LVEF were relevant risk factors and independent risk factors for heart failure in patients with different cardiac functions. NT-proBNP and MMP-9 levels are negatively correlated with LVEF in patients regardless of the cardiac function class. Therefore, attention should be paid to patients who have cardiac function in class III and above, increased NT-proBNP and MMP-9 levels and decreased LVEF in clinical practices, so as to actively prevent and treat heart failure. | |
| 651 | 4 | |a New York | |
| 651 | 4 | |a China | |
| 651 | 4 | |a United States--US | |
| 653 | |a Diabetes | ||
| 653 | |a Age | ||
| 653 | |a Heart failure | ||
| 653 | |a Hypertension | ||
| 653 | |a Risk factors | ||
| 653 | |a Physicians | ||
| 653 | |a Hospitals | ||
| 653 | |a Beta blockers | ||
| 653 | |a Pain | ||
| 653 | |a Methods | ||
| 653 | |a Dyspnea | ||
| 653 | |a Peptides | ||
| 653 | |a Cardiac function | ||
| 653 | |a Ultrasonic imaging | ||
| 653 | |a Males | ||
| 653 | |a Ejection fraction | ||
| 653 | |a Medical prognosis | ||
| 700 | 1 | |a Chen, Yanchun | |
| 700 | 1 | |a Ji, Yanni | |
| 700 | 1 | |a Yang, Song | |
| 773 | 0 | |t Experimental and Therapeutic Medicine |g vol. 15, no. 6 (2018), p. 5275 | |
| 786 | 0 | |d ProQuest |t Health & Medical Collection | |
| 856 | 4 | 1 | |3 Citation/Abstract |u https://www.proquest.com/docview/2095422183/abstract/embedded/7BTGNMKEMPT1V9Z2?source=fedsrch |
| 856 | 4 | 0 | |3 Full Text |u https://www.proquest.com/docview/2095422183/fulltext/embedded/7BTGNMKEMPT1V9Z2?source=fedsrch |
| 856 | 4 | 0 | |3 Full Text - PDF |u https://www.proquest.com/docview/2095422183/fulltextPDF/embedded/7BTGNMKEMPT1V9Z2?source=fedsrch |